Immunovant drops 7%, prices $550M stock offering [Seeking Alpha]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Seeking Alpha
Roivant Sciences, the company's controlling stockholder, has agreed to purchase shares in the offering. All of the shares are to be sold Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor DayGlobeNewswire
- Vivek Ramaswamy's Net Worth Has Nearly Doubled While He's Running For Ohio Governor [Forbes]Forbes
- Roivant Sciences (NASDAQ:ROIV) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ROIV&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZMarketBeat
- Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
ROIV
Earnings
- 11/10/25 - Beat
ROIV
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 8-K
- 12/9/25 - Form 144
- ROIV's page on the SEC website